Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1642 1645 1646 1647 1657 1674 1678
This examiner grants 58% of resolved cases
Christine J. Saoud is an examiner in Tech Center 1600 and Art Unit 1641. She has a substantial record of 767 resolved cases, with an allowance rate of 58.0 percent. This rate suggests a balanced prosecution environment where a majority of applications are eventually granted. The 767 resolved cases provide a high level of statistical confidence in these metrics.
The interview lift of 37.2 percent is a key factor for strategy. This figure indicates that interviews are effective at increasing the probability of allowance compared to the 58.0 percent overall allowance rate. Practitioners should note that the 37.2 percent lift is a reason to pursue direct communication with the examiner. This approach can be vital for navigating the complexities of Art Unit 1641.
The median days to allowance for successful cases is 1062. This duration provides a clear expectation for the timeline from filing to grant. By combining the allowance rate with the 1062 median days to allowance, applicants can develop a realistic forecast for their prosecution in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18327577 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA | Final Rejection | Janssen Biotech, Inc. |
| 18255609 | POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18121490 | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | Non-Final OA | BAYER HEALTHCARE LLC |
| 17920118 | PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE | Non-Final OA | Eli Lilly and Company |
| 17735510 | MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 18140344 | Suppression of Microglial Activation with Innate Lymphoid Cells | Non-Final OA | Janssen Pharmaceutica NV |
| 18029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy